UCB GROUP REPORTS DATA FROM KEPPRA STUDY

A A

UCB Group has presented data from a Phase III, randomized, double-blind, non-inferiority trial of Keppra (levetiracetam).

The study showed that the drug was non-inferior to controlled-release carbamazepine when used as monotherapy in the first-line treatment of adult patients with partial or generalized tonic-clonic seizures, and showed a more favorable tolerability profile1. Keppra demonstrated six- and 12-month seizure freedom rates of 73.0 percent and 56.6 percent, respectively, when used as monotherapy in newly diagnosed patients.